CDK4 and breast carcinoma: The modest monoactivity of CDK4/6 inhibitors or elotuzumab in comparison to edited tumor tissue - with antihormonal therapy approaches in breast cancer and lenalidomide plus dexamethasone in multiple myeloma, respectively, - are pivotal examples (9, 126).